免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望
发布时间：2018-12-08 09:46
【摘要】：随着程序性凋亡因子1受体(programmed death-1,PD-1)及其配体(PD-L1)抑制剂单药治疗在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的二线和一线治疗中相继取得突破性进展,晚期NSCLC的诊治策略正在逐渐发生演变和优化。免疫联合治疗扩大受益人群、提高疗效,目前已经在一线治疗领域取得初步结果,有多项III期随机对照研究正在进行中。本文将对免疫检查点抑制剂在晚期NSCLC一线治疗中的现状和前景进行综述。
[Abstract]:With the development of single drug therapy of programmed apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor in the treatment of advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC), there has been a breakthrough in the second and first line treatment of apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor. The strategy of diagnosis and treatment of advanced NSCLC is gradually evolving and optimizing. Immunization combined therapy has expanded the benefit population and improved curative effect. At present, preliminary results have been obtained in the field of first-line treatment, and many randomized controlled studies of III stage are under way. This article reviews the current status and prospects of immunocheckpoint inhibitors in the first-line treatment of advanced NSCLC.
【作者单位】： 浙江省肿瘤医院;
【分类号】：R734.2
，
本文编号：2368140
[Abstract]:With the development of single drug therapy of programmed apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor in the treatment of advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC), there has been a breakthrough in the second and first line treatment of apoptosis factor 1 receptor (programmed death-1,PD-1) and its ligand (PD-L1) inhibitor. The strategy of diagnosis and treatment of advanced NSCLC is gradually evolving and optimizing. Immunization combined therapy has expanded the benefit population and improved curative effect. At present, preliminary results have been obtained in the field of first-line treatment, and many randomized controlled studies of III stage are under way. This article reviews the current status and prospects of immunocheckpoint inhibitors in the first-line treatment of advanced NSCLC.
【作者单位】： 浙江省肿瘤医院;
【分类号】：R734.2
，
本文编号：2368140
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2368140.html
